We have noted the great potential of the Multiple Sclerosis Drug Alemtuzumab in a previous posts [1]

Note that current research see it prescribed for the Relapsing Remitting (RRMS) form, which is indeed what the clinical trials mentioned in [2] were about, even though their title was much more general.

Rate of success is impressive,quoting [2]:

“…The study showed that after 2 years, almost a quarter of patients had achieved a disease activity–free state compared with none of those treated with interferon…”

Also the drug’s injection is grouped in 5 consecutive days, the first year and 3 consecutive days the second year, which much better than the year-long administration of many interferons.

The risks are substantial, though:

“…that side effects of the drug have encompassed potentially serious autoimmune diseases, including thyroid disorders and immune thrombocytopenia, both of which require careful monitoring and management…”

This is why the drug is considered only for difficult MS cases

Alemtuzumab binds to the surface of a protein (CD-52) present on the surface of certain lymphocytes, marking them for destruction.

This remarkable MS success story has a murky marketing aspect: The drug existed as a Leukemia medication under the name of Campath [3], but was put on a restricted market path through patient access programs”[4]

Sucuri

Alexa

OUR MISSION

Health research is moving at such a fast pace that one needs an "ear to the ground" to follow and sift through the immense amount of data coming our way. We include classical and alternative medicine,nutrition, pollution and environmental issues. We also have a bit of a contrarian approach, so expect us to question medical and health fads. MediNewsDigest particularly follow autoimmune conditions, diabetes and related issues as well as heart conditions.

Disclaimer

The MediNewsDigest and it's posts are to bring your attention to topics that could benefit you and should discussed with your Doctor or other medical professional. The staff is not medically trained and posts are of a journalistic nature and not in lieu of medical advice. MediNewsDigest will not be held liable for any damages incurred using the Blogs, data or links provided

Meta

Feedjit

Archives

Disclaimer

The MediNewsDigest and it's posts are to bring your attention to topics that could benefit you and should discussed with your Doctor or other medical professional. The staff is not medically trained and posts are of a journalistic nature and not in lieu of medical advice. MediNewsDigest will not be held liable for any damages incurred using the Blogs, data or links provided